B型利钠肽在肝硬化性心肌病中的作用进展

王亚洁; 陈丽萍; 尚祉胤; 杨敬貌; 艾迎春; 程计林

doi:10.3969/j.issn.1001-5256.2018.05.040

B型利钠肽在肝硬化性心肌病中的作用进展

DOI: 10.3969/j.issn.1001-5256.2018.05.040

1. 上海市(复旦大学附属)公共卫生临床中心
2. 佳木斯大学附属第一医院消化内科
3. 温州医科大学附属第一医院消化内科

详细信息

中图分类号: R542.2;R575.2
计量
- 文章访问数: 1980
- HTML全文浏览量: 48
- PDF下载量: 502
- 被引次数: 0
出版历程
- 出版日期: 2018-05-20

Advances in the effect of B-type natriuretic peptide and its significance in patients with cirrhotic cardiomyopathy

Shanghai Public Health Clinical Center, Fudan University, Shanghai 201058, China

摘要

摘要:
肝硬化患者常见有心脏负荷增大,心肌收缩功能和舒张功能受损,导致心肌结构异常,当处于应激状态时可出现心力衰竭症状,被称为肝硬化性心肌病(CCM)。由于起病隐匿,目前对于CCM关注较少。B型利钠肽(BNP)由心肌细胞分泌,能够敏感地反映心室功能变化,被广泛应用于心血管疾病的发病、治疗及预后等方面的评估。BNP一直以来在呼吸系统疾病、肾脏疾病的诊疗方面均显示出重要作用,同时近期研究发现BNP在肝硬化患者中明显升高,与肝硬化腹水、静脉曲张、肝功能损伤严重程度紧密相关,并且在CCM无症状时,即可对心肌损伤发挥一定的提示作用。综述了BNP在CCM中的表达及意义。
- 利钠肽,脑 /
- 肝硬化 /
- 心肌疾病 /
- 综述
Abstract:
Cirrhotic patients often have an increased cardiac load and impaired myocardial systolic and diastolic functions, which further cause abnormal myocardial structure, and such patients may develop the symptoms of heart failure under stress, which is called cirrhotic cardiomyopathy ( CCM) . This disease attracts little attention due to its insidious onset. B-type natriuretic peptide ( BNP) is secreted by cardiomyocytes and can sensitively reflect the change in ventricular function, and it is widely used in the pathogenesis, treatment, and prognosis of cardiovascular diseases. BNP plays an important role in the diagnosis and treatment of respiratory and renal diseases, and meanwhile, recent studies have shown a significant increase in BNP in cirrhotic patients, which is closely associated with the severity of cirrhotic ascites, varices, and liver dysfunction. BNP can also reveal myocardial injury when there are no obvious symptoms of CCM. This article reviews the expression of BNP and its significance in patients with CCM.
- natriuretic peptide, brain /
- liver cirrhosis /
- cardiomyopathies /
- review

HTML全文

参考文献(39)

[1]WIESE S, HOVE JD, BENDTSEN F, et al.Cirrhotic cardiomyopathy:pathogenesis and clinical relevance[J].Nat Rev Gastroenterol Hepatol, 2014, 11 (3) :177-186.

[2]MOLLER S, BENDTSEN F.Cirrhotic multiorgan syndrome[J].Dig Dis Sci, 2015, 60 (11) :3209-3225.

[3]GENOT N, MEWTON N, BRESSON D, et al.Bioelectrical impedance analysis for heart failure diagnosis in the ED[J].Am J Emerg Med, 2015, 33 (8) :1025-1029.

[4]GOPAL DJ, IQBAL MN, MAISEL A.Updating the role of natriuretic peptide levels in cardiovascular disease[J].Postgrad Med, 2011, 123 (6) :102-113.

[5]LJUBICˇIC'N, GOMERCIC M, ZEKANOVIC D, et al.New insight into the role of NT-pro BNP in alcoholic liver cirrhosis as a noninvasive marker of esophageal varices[J].Croat Med J, 2012, 53 (4) :374-378.

[6]TUXUNGULI T, AIERKEN A, XIE X, et al.Association study of plasma NT-pro BNP levels and severity of acute coronary syndrome[J].Genet Mol Res, 2014, 13 (3) :5754-5757.

[7]NIU JM, MA ZL, XIE C, et al.Association of plasma B-type natriuretic peptide concentration with myocardial infarct size in patients with acute myocardial infarction[J].Genet Mol Res, 2014, 13 (3) :6177-6183.

[8]GARIANI K, DELABAYS A, PERNEGER TV, et al.Use of brain natriuretic peptide to detect previously unknown left ventricular dysfunction in patients with acute exacerbation of chronic obstructive pulmonary disease[J].Swiss Med Wkly, 2011, 141:w13298.

[9]GALE CP, WHITE JE, HUNTER A, et al.Predicting mortality and hospital admission in patients with COPD:significance of NT pro-BNP, clinical and echocardiographic assessment[J].J Cardiovasc Med (Hagerstown) , 2011, 12 (9) :613-618.

[10]CHOU YH, CHEN YF, PAN SY, et al.The role of brain natriuretic peptide in predicting renal outcome and fluid management in critically ill patients[J].J Formos Med Assoc, 2015, 114 (12) :1187-1196.

[11]de CAL M, HAAPIO M, CRUZ DN, et al.B-type natriuretic Peptide in the critically ill with acute kidney injury[J].Int J Nephrol, 2011, 2011:951629.

[12]YOSHITOMI R, NAKAYAMA M, SAKOH T, et al.Plasma Btype natriuretic peptide concentration is independently associated with kidney function decline in Japanese patients with chronic kidney disease[J].J Hypertens, 2016, 34 (4) :753-761.

[13]FATTOUH AM, EL-SHABRAWI MH, MAHMOUD EH, et al.Evaluation of cardiac functions of cirrhotic children using serum brain natriuretic peptide and tissue Doppler imaging[J].Ann Pediatr Cardiol, 2016, 9 (1) :22-28.

[14]SHI LY, JIN R, LIN CJ, et al.B-type natriuretic peptide and cirrhosis progression[J].Genet Mol Res, 2015, 14 (2) :5188-5196.

[15]RADVAN M, SVOBODA P, RADVANOVA J, et al.Brain natriuretic peptide in decompensation of liver cirrhosis in non-cardiac patients[J].Hepatogastroenterology, 2009, 56 (89) :181-185.

[16]METWALY A, KHALIK AA, NASR FM, et al.Brain natriuretic peptide in liver cirrhosis and fatty liver:correlation with cardiac performance[J].Electron Physician, 2016, 8 (2) :1984-1993.

[17]RUNYON BA, COMMITTEE APG.Management of adult patients with ascites due to cirrhosis:an update[J].Hepatology, 2009, 49 (6) :2087-2107.

[18]LICATA A, CORRAO S, PETTA S, et al.NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis[J].PLo S One, 2013, 8 (8) :e68364.

[19]RUNYON BA.Cardiac ascites:a characterization[J].J Clin Gastroenterol, 1988, 10 (4) :410-412.

[20]UDDIN MS, HOQUE MI, ISLAM MB, et al.Serum-ascites albumin gradient in differential diagnosis of ascites[J].Mymensingh Med J, 2013, 22 (4) :748-754.

[21]BEGUM N, AFROZA A, KARIM BM.Evaluation of correlation between high serum-ascites albumin gradient and the upper gastrointestinal endoscopic parameters in children presenting with portal hypertension with ascites[J].Mymensingh Med J, 2014, 23 (4) :703-708.

[22]FARIAS AQ, SILVESTRE OM, GARCIA-TSAO G, et al.Serum B-type natriuretic peptide in the initial workup of patients with new onset ascites:a diagnostic accuracy study[J].Hepatology, 2014, 59 (3) :1043-1051.

[23]ESPINOSA MD, OLMEDO C, MUFFAK-GRANERO K, et al.Preoperative natriuretic peptide-B values and ascites in male liver transplant recipients[J].Transplant Proc, 2011, 43 (3) :705-707.

[24]KRISHNAN A, SRINIVASAN V, VENKATARAMAN J.Variceal recurrence, rebleeding rates and alterations in clinical and laboratory parameters following post-variceal obliteration using endoscopic sclerotherapy[J].J Dig Dis, 2012, 13 (11) :596-600.

[25]BORTOLUZZI A, CEOLOTTO G, GOLA E, et al.Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites:molecular mechanisms[J].Hepatology, 2013, 57 (1) :266-276.

[26]MANI AR, IPPOLITO S, CENTELLES MN, et al.Nitric oxidedependent bradycardia in mutant analbuminemic rats[J].Biochem Pharmacol, 2012, 84 (8) :1062-1069.

[27]MERCANTINI P, di SOMMA S, MAGRINI L, et al.Preoperative brain natriuretic peptide (BNP) is a better predictor of adverse cardiac events compared to preoperative scoring system in patients who underwent abdominal surgery[J].World J Surg, 2012, 36 (1) :24-30.

[28]MATUCHANSKY C.Bacterial translocation in liver cirrhosis:site and role in fibrogenesis[J].J Hepatol, 2014, 61 (3) :709-710.

[29]PADILLO J, RIOJA P, MUNOZ-VILLANUEVA MC, et al.BNP as marker of heart dysfunction in patients with liver cirrhosis[J].Eur J Gastroenterol Hepatol, 2010, 22 (11) :1331-1336.

[30]VOIOSU A, WIESE S, VOIOSU T, et al.Bile acids and cardiovascular function in cirrhosis[J].Liver Int, 2017, 37 (10) :1420-1430.

[31]HAMMAMI R, BOUDABBOUS M, JDIDI J, et al.Cirrhotic cardiomyopathy:is there any correlation between the stage of cardiac impairment and the severity of liver disease?[J].Libyan J Med, 2017, 12 (1) :1283162.

[32]MERLI M, CALICCHIA A, RUFFA A, et al.Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease[J].Eur J Intern Med, 2013, 24 (2) :172-176.

[33]FERNANDEZ JJO, MOYA AF, RODRIGUEZ AL, et al.Study of arterial blood gases in liver cirrhosis with and without ascites[J].Rev Esp Enferm Dig, 1996, 88 (3) :197-201.

[34]NAQVI IH, MAHMOOD K, NAEEM M, et al.The heart matters when the liver shatters!Cirrhotic cardiomyopathy:frequency, comparison, and correlation with severity of disease[J].Prz Gastroenterol, 2016, 11 (4) :247-256.

[35]MERLI M, TORROMEO C, GIUSTO M, et al.Survival at 2 years among liver cirrhotic patients is influenced by left atrial volume and left ventricular mass[J].Liver Int, 2017, 37 (5) :700-706.

[36]MOCARZEL LO, BICCA J, JARSKE L, et al.Cirrhotic cardiomyopathy:another case of a successful approach to treatment of hepatorenal syndrome[J].Case Rep Gastroenterol, 2016, 10 (3) :531-537.

[37]MOCARZEL L, LANZIERI P, NASCIMENTO J, et al.Hepatorenal syndrome with cirrhotic cardiomyopathy:case report and literature review[J].Case Rep Hepatol, 2015, 2015:573513.

[38]KRAG A, BENDTSEN F, BURROUGHS AK, et al.The cardiorenal link in advanced cirrhosis[J].Med Hypotheses, 2012, 79 (1) :53-55.

[39]KOMEICHI H, MOREAU R, CAILMAIL S, et al.Blunted natriuresis and abnormal systemic hemodynamic responses to C-type and brain natriuretic peptides in rats with cirrhosis[J].J Hepatol, 1995, 22 (3) :319-325.

施引文献

资源附件(0)

访问统计